Brokerages Set Aytu BioPharma Inc. (NASDAQ:AYTU) PT at $9.33

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) have been assigned a consensus rating of “Hold” from the five brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $9.3333.

A number of equities analysts have commented on AYTU shares. Ascendiant Capital Markets upped their target price on shares of Aytu BioPharma from $12.50 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a report on Friday, January 9th. Finally, Zacks Research raised shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Monday, November 24th.

Aytu BioPharma Price Performance

Shares of Aytu BioPharma stock opened at $2.70 on Thursday. Aytu BioPharma has a 12-month low of $0.95 and a 12-month high of $3.07. The company’s fifty day simple moving average is $2.42 and its two-hundred day simple moving average is $2.33. The firm has a market cap of $27.51 million, a PE ratio of -0.89 and a beta of 0.32. The company has a quick ratio of 1.08, a current ratio of 1.23 and a debt-to-equity ratio of 0.45.

Aytu BioPharma (NASDAQ:AYTU) last announced its earnings results on Thursday, November 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). The business had revenue of $13.89 million for the quarter, compared to analyst estimates of $17.92 million. Aytu BioPharma had a negative net margin of 20.52% and a positive return on equity of 17.86%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Stonepine Capital Management LLC boosted its holdings in shares of Aytu BioPharma by 75.3% in the 2nd quarter. Stonepine Capital Management LLC now owns 812,676 shares of the company’s stock valued at $1,772,000 after buying an additional 348,955 shares in the last quarter. AWM Investment Company Inc. acquired a new position in Aytu BioPharma in the second quarter valued at $1,351,000. Two Sigma Investments LP boosted its stake in Aytu BioPharma by 96.2% in the third quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock valued at $129,000 after acquiring an additional 33,701 shares in the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of Aytu BioPharma during the third quarter worth about $117,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Aytu BioPharma during the second quarter worth about $78,000. 33.49% of the stock is currently owned by hedge funds and other institutional investors.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.